DalCor Announces Expansion and Accelerated Enrollment of the dal-GenE Clinical Trial
DalCor today announced that the company will increase enrollment in its ongoing Phase 3 clinical trial of dalcetrapib from 5000 to 6000 patients.
DalCor Pharmaceuticals Appoints Dr. Fouzia Laghrissi-Thode to the Board of Directors
DalCor Pharmaceuticals today announced the appointment of Dr. Fouzia Laghrissi-Thode to its Board of Directors. Dr. Laghrissi-Thode is VicePresident at AstraZeneca.
DalCor Achieves 50 percent Enrollment Milestone for Phase 3 Cardiovascular Trial — Dalcetrapib Studied in Genetically Targeted Patients with Acute Coronary Syndrome —
DalCor Pharmaceuticals today announced it has exceeded its enrollment schedule with 50 percent of patients randomized in its Phase 3 “dalGenE” clinical trial. More than 2,500 out of 5,000 expected patients with acute coronary syndrome (ACS) and the AA genotype at variant rs1967309 in the ADCY9 gene have entered into this cardiovascular outcomes study of dalcetrapib.
DalCor Pharmaceuticals to Present at Bloom Burton & Co Healthcare Investor Conference 2017
DalCor Pharmaceuticals today announced that senior management will present at the Bloom Burton & Co.
DalCor Pharmaceuticals to Present at Needham & Co. Healthcare Conference
DalCor Pharmaceuticals today announced that senior management will participate at the 16th Needham & Co. Healthcare Conference taking place April 4-5, 2017 at the Westin Grand Central in New York.
DalCor’s Phase 3 Cardiovascular Trial, dal-GenE, Exceeds Targeted Enrollment Schedule — Dalcetrapib Studied in Genetically Distinct Patients with Acute Coronary Syndrome
DalCor Pharmaceuticals today announced it is ahead of the enrollment schedule with the randomization of over 1,000 patients of the expected 5,000 patients planned for the Phase 3 “dal-GenE” clinical trial, a cardiovascular outcomes study of dalcetrapib in patients with acute coronary syndrome (ACS) and the AA genotype in the ADCY9 gene.
DalCor Announces Data to be Presented at the American Heart Association Scientific Sessions 2016 in New Orleans
DalCor Pharmaceuticals today announced the key investigator in dalcetrapib trials, Jean-Claude Tardif, C.M., M.D., FRCPC, FACC, FAHA, FESC, will present data at the American Heart Association Scientific Sessions 2016 (AHA) during the Abstract Rapid Fire Session on Sunday, November 13, 2016 in New Orleans.
DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial
DalCor Pharmaceuticals today announced the opening of multiple international clinical trial sites in New Zealand and Europe for its Phase 3 dal-GenE clinical trial, a cardiovascular outcomes study of dalcetrapib in patients with acute coronary syndrome (ACS) and the AA genotype in the ADCY9 gene.
DalCor’s Dalcetrapib Demonstrates Genotype-Dependent Effects of Cholesterol Efflux and Inflammation in Data
DalCor Pharmaceuticals and The Montreal Heart Institute today announced the publication in Circulation Cardiovascular Genetics of data demonstrating dalcetrapib’s genotype-dependent effects on high-sensitivity C-reactive protein (hs-CRP) from the prospective analysis of a randomized, placebo controlled clinical trial that included 5243 genotyped patients with acute coronary syndrome (ACS).
DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial
DalCor Pharmaceuticals today announced it has randomzied the first patient in the Phase 3 “dal-GenE” clinical trial, a cardiovascular outcomes study of dalcetrapib in patients with acute coronary syndrome (ACS) and the AA genotype in the ADCY9 gene. The worldwide clinical trial will be led by the Montreal Heart Institute.
